Drug protein binding and the nephrotic syndrome

Area of Science:

• Pharmacology
• Clinical Chemistry

Background:

• Reduced plasma albumin concentration in nephrotic syndrome typically decreases plasma protein binding of highly bound drugs.
• This leads to an increased unbound drug fraction, while the absolute free concentration remains relatively stable due to compensatory reductions in total plasma concentration.

Purpose of the Study:

• To explain the impact of reduced plasma albumin on drug binding and interpret plasma drug levels in hypoalbuminemic patients.
• To provide guidance on drug dosing strategies in conditions affecting plasma protein binding.

Main Methods:

• The study discusses the relationship between plasma albumin concentration and the protein binding of highly bound drugs.
• It analyzes the consequences of altered protein binding on total and unbound drug concentrations and clearance.

Main Results:

• Phenytoin's protein binding is closely linked to plasma albumin levels, allowing binding estimation without specialized techniques.
• While mean steady-state total plasma concentrations of highly bound drugs are unaffected in nephrotic syndrome, unbound levels fluctuate more significantly between doses.
• Reduced protein binding increases total plasma clearance, influenced by elimination rate constant and volume of distribution.

Conclusions:

• Accurate interpretation of plasma drug levels requires knowledge of protein binding, especially in hypoalbuminemic patients where reduced total concentration may still be effective.
• Greater fluctuations in unbound drug levels may explain increased toxicity incidence, suggesting shorter dosing intervals are preferable to dose reduction.
• Understanding these pharmacokinetic changes is crucial for optimizing drug therapy in patients with altered plasma protein levels.